CASEY DE GRAAF: Open Payments
NPI 1174027098 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,399 in 54 payments from 23 companies in 2025. Trend: 2023 $738 · 2024 $1,386 · 2025 $1,399
Food & beverage: $1,356Education: $43
| Company | Payments | Amount |
|---|---|---|
| SHIELD THERAPEUTICS INC | 4 | $198 |
| Astellas Pharma Global Development | 3 | $167 |
| AstraZeneca Pharmaceuticals LP | 6 | $137 |
| Novartis Pharmaceuticals Corporation | 5 | $118 |
| Merck Sharp & Dohme LLC | 5 | $110 |
| Madrigal Pharmaceuticals | 4 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Genentech USA, Inc. | 3 | $70 |
| Lilly USA, LLC | 2 | $44 |
| SOBI, INC | 2 | $44 |
Products named: ACCRUFER, Veozah, KEYTRUDA, REZDIFFRA, ENHERTU, LUTATHERA, VERZENIO, Doptelet.
Industry payments across OK — which companies pay providers there.
